Skip to main content

Table 2 Association between TIMP-1 status and patient demographics, disease characteristics, and prior therapy

From: TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group

   TIMP-1 negative    TIMP-1 positive   
Characteristics No.   (%) No.   (%) Pc
No. of patients 54    210    
Regimen        0.36
  Docetaxel and Gemcitabine 25   (46.3) 112   (53.3)  
  Docetaxel 29   (53.7) 98   (46.7)  
Median age at randomization, years   60    59   0.79e
  Range   37-74    30-75   
ECOG performance status        0.91
  0-1 47   (87.0) 176   (83.8)  
  2 6   (11.1) 26   (12.4)  
  Unknown 1   (1.9) 8   (3.8)  
Stage of disease        0.58
  Locally advanced 3   (5.6) 19   (9.0)  
  Metastatic 51   (94.4) 191   (91.0)  
No. of metastatic sites        0.40
  1 12   (22.2) 66   (31.4)  
  2 22   (40.7) 71   (33.8)  
  ≥ 3 20   (37.0) 73   (34.8)  
Type of metastatic site        
  Visceral 31   (57.4) 119   (56.7) 1.00
  Lung 17   (31.5) 61   (29.0) 0.87
  Liver 18   (33.3) 81   (38.6) 0.44
  Non-visceral 23   (42.6) 91   (43.3)  
  Bone 33   (61.1) 142   (67.6) 0.42
Hormone receptor status        0.30
  Positive 42   (77.8) 148   (70.5)  
  Negative 11   (20.4) 59   (28.1)  
  Unknown 1   (1.9) 3   (1.4)  
HER2 statusa        0.66
  Normal/deletion 40   (74.1) 172   (81.9)  
  Amplification 8   (14.8) 29   (13.8)  
  Unknown 6   (11.1) 9   (4.3)  
PAM50 subtype        0.89
  Luminal A 15   (27.8) 63   (30.0)  
  Luminal B 20   (37.0) 74   (35.2)  
  Basal-like 7   (13.0) 33   (15.7)  
  HER2-enriched 11   (20.4) 35   (16.7)  
  Unknown 1   (1.9) 5   (2.4)  
Prior chemotherapy        
  Total 37   (68.5) 151   (71.9) 0.62
  (Neo)adjuvant 23   (42.6) 104   (49.5) 0.45
   Anthracycline 14   (25.9) 57   (27.1)  
   Non-anthracycline 9   (16.7) 47   (22.4)  
  Locally advanced/metastatic 21   (38.9) 81   (38.6) 1.00
   Anthracycline 15   (27.8) 71   (33.8)  
   Non-anthracycline 6   (11.1) 10   (4.8)  
Hormonal therapy        
  Total 36   (66.7) 137   (65.2) 0.87
  Adjuvant 24   (44.4) 95   (45.2) 1.00
  Locally advanced/metastatic 27   (50.0) 93   (44.3) 0.54
Radiation therapy 33   (61.1) 124   (59.0) 0.88
Disease-free interval, monthsb        
  Median   36    31   0.41e
  Range   0-224    0-250   
  1. aRetrospective analysis, primary tumor only.
  2. bTime interval from diagnosis of primary cancer to recurrence.
  3. cFisher's exact test, unknown values excluded from tests.
  4. eWilcoxon test.
  5. Abbreviations: ECOG Eastern Cooperative Oncology Group, HER2 Human epidermal growth factor receptor 2, TIMP-1 Tissue inhibitor of metalloproteinases-1.